With a fresh FDA endorsement for its drug plozasiran, Pasadena-based Arrowhead Pharmaceuticals has successfully broken through to the commercial realm. More: Arrowhead strikes true with 1st FDA approval, but Ionis competition looms Source: fierce
read more
Munich-based start-up backed by Frontline Ventures and Y Combinator eyes global expansion More: Cellbyte raises .75m to slash drug launch timelines with AI Source: News
read moreThe bankruptcy reorganization plan will deliver $7.4 billion to creditors, including an up-to-$7 billion contribution from the Sackler family, while Purdue Pharma will dissolve into a new company called Knoa Pharma. More: Sackler family, Purdue Pharma's .4B settlement plan wins
read more
Six new Grand Challenges aim to tackle drug resistance and accelerate antibiotic discovery More: GSK and Imperial launch £45m AI-powered AMR research drive Source: News
read moreThe distinction is important because under Avadel’s existing transaction agreement with Alkermes, the latter company now has five business days to “discuss or negotiate in good faith” any potential amendments to its prior offer. More: Avadel views Lundbeck's .4B buyout
read morePositive results from a proof-of-concept study evaluating Merck’s Winrevair pave the way for further study of the activin signaling inhibitor as a potential treatment for a subset of heart failure patients. More: Merck advances Winrevair in subset of heart failure
read more© 1994 - 2026 B.M. Pharmaceuticals